{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:05:33Z","timestamp":1791475533431,"version":"4.3.4"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ejps.2019.105170","type":"journal-article","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T19:48:17Z","timestamp":1574797697000},"page":"105170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"special_numbering":"C","title":["Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen"],"prefix":"10.1016","volume":"143","author":[{"given":"Ioannis","family":"Loisios-Konstantinidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Cristofoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoletta","family":"Fotaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9066-3980","authenticated-orcid":false,"given":"Jennifer","family":"Dressman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2019.105170_bib0001","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.addr.2007.05.008","article-title":"Solubility of sparingly-soluble ionizable drugs","volume":"59","author":"Avdeef","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2019.105170_bib0002","doi-asserted-by":"crossref","DOI":"10.1023\/A:1007526826979","article-title":"pH-Metric solubility. 2: correlation between the acid-base titration and formulations for use in early animal bioavailability and toxicity studies. later in development, solubility takes on a broader","volume":"17","author":"Avdeef","year":"2000","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2019.105170_bib0003","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2165\/00003088-199500292-00016","article-title":"The pharmacokinetic and pharmacodynamic interactions between the 5-Lipoxygenase inhibitor zileuton and the cyclo-oxygenase inhibitor naproxen in human volunteers","volume":"29","author":"Awni","year":"1995","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2019.105170_bib0004","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1002\/jps.24474","article-title":"Application of physiologically based absorption modeling for amphetamine salts drug products in generic drug evaluation","volume":"104","author":"Babiskin","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105170_bib0005","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejps.2013.09.010","article-title":"Is the full potential of the biopharmaceutics classification system reached?","volume":"57","author":"Bergstr\u00f6m","year":"2014","journal-title":"Eur. J. Pharm. Sci"},{"key":"10.1016\/j.ejps.2019.105170_bib0006","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1124\/dmd.106.011569","article-title":"Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance","volume":"35","author":"Brown","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2019.105170_bib0007","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.1002\/jps.22217","article-title":"The developability classification system: application of biopharmaceutics concepts to formulation development","volume":"99","author":"Butler","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105170_bib0008","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/bdd.2510150204","article-title":"Comparative in vitro and in vivo bioavailability of naproxen from tablet and caplet formulations","volume":"15","author":"Charles","year":"1994","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2019.105170_bib0009","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/jps.2600670918","article-title":"pH\u2013Solubility profiles of organic carboxylic acids and their salts","volume":"67","author":"Chowhan","year":"1978","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105170_bib0010","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/jps.23515","article-title":"A comparative analysis of biopharmaceutics classification system and biopharmaceutics drug disposition classification system: a cross-sectional survey with 500 bioequivalence studies","volume":"102","author":"Cristofoletti","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105170_bib0011","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1016\/j.xphs.2016.08.024","article-title":"Bridging the gap between in vitro dissolution and the time course of ibuprofen-mediating pain relief","volume":"105","author":"Cristofoletti","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105170_bib0012","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1016\/j.xphs.2015.11.033","article-title":"Differences in food effects for 2 weak bases with similar bcs drug-related properties: what is happening in the intestinal lumen?","volume":"105","author":"Cristofoletti","year":"2016","journal-title":"J. Pharm. Sci"},{"key":"10.1016\/j.ejps.2019.105170_bib0013","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/j.xphs.2018.06.013","article-title":"Past, present, and future of bioequivalence: improving assessment and extrapolation of therapeutic equivalence for oral drug products","volume":"107","author":"Cristofoletti","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105170_bib0014","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2165\/00003088-199732040-00002","article-title":"Clinical pharmacokinetics of naproxen","volume":"32","author":"Davies","year":"1997","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2019.105170_bib0015","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1208\/s12248-008-9034-7","article-title":"Clinical relevance of dissolution testing in quality by design","volume":"10","author":"Dickinson","year":"2008","journal-title":"AAPS J"},{"key":"10.1016\/j.ejps.2019.105170_bib0016","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejps.2017.07.035","article-title":"Virtual bioequivalence for achlorhydric subjects: the use of pbpk modelling to assess the formulation-dependent effect of achlorhydria","volume":"109","author":"Doki","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105170_bib0017","unstructured":"European Medicines Agency (EMA), 2018a. Committee for medicinal products for human use (CHMP) guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation."},{"key":"10.1016\/j.ejps.2019.105170_bib0018","unstructured":"European Medicines Agency (EMA), 2018b. Committee for medicinal products for human use (CHMP) guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation."},{"key":"10.1016\/j.ejps.2019.105170_bib0019","first-page":"139","article-title":"Pharmacokinetics of naproxen at two dosage regimens in healthy volunteers","volume":"24","author":"Franssen","year":"1986","journal-title":"Int. J. Clin. Pharmacol. Ther. Toxicol."},{"key":"10.1016\/j.ejps.2019.105170_bib0020","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2982.2007.00904.x","article-title":"Intersubject and intrasubject variability of gastric volumes in response to isocaloric liquid meals in functional dyspepsia and health","volume":"19","author":"Fruehauf","year":"2007","journal-title":"Neurogastroenterol. Motil."},{"key":"10.1016\/j.ejps.2019.105170_bib0021","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ejpb.2015.05.015","article-title":"Advances in the design of fasted state simulating intestinal fluids: FaSSIF-V3","volume":"94","author":"Fuchs","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2019.105170_bib0022","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3109\/03009748809098754","article-title":"Steady state pharmacokinetics of naproxen in elderly rheumatics compared with young volunteers","volume":"17","author":"G\u00f8tzsche","year":"1988","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.ejps.2019.105170_bib0023","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ejpb.2018.03.002","article-title":"Interindividual and intraindividual variability of fasted state gastric fluid volume and gastric emptying of water","volume":"127","author":"Grimm","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2019.105170_bib0024","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1526-4610.2009.01606.x","article-title":"Distinct pharmacokinetic profile and safety of a fixed-dose tablet of sumatriptan and naproxen sodium for the acute treatment of migraine","volume":"50","author":"Haberer","year":"2010","journal-title":"Headache"},{"key":"10.1016\/j.ejps.2019.105170_bib0025","unstructured":"Heimbach, T., Laisney, M., Samant, T., Elmeliegy, M., Wu, F., Hanna, I., Lin, W., Zhang, J., Dodd, S., Nguyen-Trung, A.-.T., Tian, H., Vogg, B., Beato, S., Garad, S., Choudhury, S., Ren, X., Mueller-Zsigmondy, M., Einolf, H., Umehara, K., Hourcade-Potelleret, F., He, H.,.PBPK modeling and simulations of oral drug absorption\/food effect\/ppi \/PBIVIVC: Opportunities and challenges dissolution and translational modeling strategies enabling patient-centric product development. 2017."},{"key":"10.1016\/j.ejps.2019.105170_bib0026","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1208\/s12248-019-0298-x","article-title":"Dissolution and translational modeling strategies toward establishing an in vitro-in vivo link\u2014a workshop summary report","volume":"21","author":"Heimbach","year":"2019","journal-title":"AAPS J"},{"key":"10.1016\/j.ejps.2019.105170_bib0027","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ejps.2014.07.008","article-title":"Gastrointestinal transfer: in vivo evaluation and implementation in in vitro and in silico predictive tools","volume":"63","author":"Hens","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105170_bib0028","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1208\/s12248-009-9099-y","article-title":"Population-based mechanistic prediction of oral drug absorption","volume":"11","author":"Jamei","year":"2009","journal-title":"AAPS J"},{"key":"10.1016\/j.ejps.2019.105170_bib0029","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.ejpb.2013.09.009","article-title":"Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac","volume":"85","author":"Kambayashi","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2019.105170_bib0030","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/psp4.12088","article-title":"Towards a best practice approach in pbpk modeling: case example of developing a unified efavirenz model accounting for induction of CYPs 3A4 and 2B6","volume":"5","author":"Ke","year":"2016","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105170_bib0031","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/psp4.12134","article-title":"Applied concepts in pbpk modeling: how to build a pbpk\/pd model","volume":"5","author":"Kuepfer","year":"2016","journal-title":"CPT pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105170_bib0032","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF02090069","article-title":"Inter- and intrasubject variability of solid and liquid gastric emptying parameters. a scintigraphic study in healthy subjects and diabetic patients","volume":"39","author":"Lartigue","year":"1994","journal-title":"Dig. Dis. Sci."},{"issue":"9 SUPPL","key":"10.1016\/j.ejps.2019.105170_bib0033","first-page":"396","article-title":"Human effective permeability data for furosemide, hydrochlorothiazide, ketoprofen and naproxen to be used in the proposed biopharmaceutical classification for IR-products","volume":"12","author":"Lennernas","year":"1995","journal-title":"Pharm. Res. (New York)"},{"key":"10.1016\/j.ejps.2019.105170_bib0034","doi-asserted-by":"crossref","first-page":"402","DOI":"10.2165\/00003088-198712060-00002","article-title":"Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs","volume":"12","author":"Lin","year":"1987","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2019.105170_bib0035","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/jphp.13070","article-title":"Application of the relationship between pharmacokinetics and pharmacodynamics in drug development and therapeutic equivalence: a pearrl review","volume":"71","author":"Loisios-Konstantinidis","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105170_bib0036","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1021\/acs.molpharmaceut.7b00198","article-title":"Validation of dissolution testing with biorelevant media: an orbito study","volume":"14","author":"Mann","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2019.105170_bib0037","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejpb.2015.03.009","article-title":"In-vitro simulation of luminal conditions for evaluation of performance of oral drug products: choosing the appropriate test media","volume":"93","author":"Markopoulos","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2019.105170_bib0038","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/jps.2600750907","article-title":"Dissolution of acidic and basic compounds from the rotating disk: influence of convective diffusion and reaction","volume":"75","author":"McNamara","year":"1986","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105170_bib0039","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/cpt.1242","article-title":"Maximizing the role of physiologically based oral absorption modeling in generic drug development","volume":"105","author":"Mitra","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2019.105170_bib0040","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/jps.2600700103","article-title":"Dissolution kinetics of carboxylic acids I: effect of pH under unbuffered conditions","volume":"70","author":"Mooney","year":"1981","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105170_bib0041","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/jps.2600700104","article-title":"Dissolution kinetics of carboxylic acids II: effect of buffers","volume":"70","author":"Mooney","year":"1981","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105170_bib0042","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/jps.2600701218","article-title":"Dissolution kinetics of phenylbutazone","volume":"70","author":"Mooney","year":"1981","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105170_bib0043","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/(SICI)1099-081X(199605)17:4<355::AID-BDD960>3.0.CO;2-N","article-title":"Dose dependent pharmacokinetics of naproxen in man","volume":"17","author":"Niazi","year":"1996","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2019.105170_bib0044","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0022-3565(24)36999-X","article-title":"The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data","volume":"283","author":"Obach","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2019.105170_bib0045","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1208\/s12248-016-9965-3","article-title":"Development of a novel simplified pbpk absorption model to explain the higher relative bioavailability of the OROS\u00ae formulation of oxybutynin","volume":"18","author":"Olivares-Morales","year":"2016","journal-title":"AAPS J"},{"key":"10.1016\/j.ejps.2019.105170_bib0046","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1023\/A:1015970502993","article-title":"Dissolution of lonizable drugs in buffered and unbuffered solutions","volume":"05","author":"Ozturk","year":"1988","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2019.105170_bib0047","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejpb.2018.05.033","article-title":"Gastric emptying and intestinal appearance of nonabsorbable drugs phenol red and paromomycin in human subjects: a multi-compartment stomach approach","volume":"129","author":"Paix\u00e3o","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2019.105170_bib0048","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijpharm.2012.03.019","article-title":"Prediction of the human oral bioavailability by using in vitro and in silico drug related parameters in a physiologically based absorption model","volume":"429","author":"Paix\u00e3o","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2019.105170_bib0049","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1208\/s12248-014-9639-y","article-title":"Physiologically based absorption modelling to predict the impact of drug properties on pharmacokinetics of bitopertin","volume":"16","author":"Parrott","year":"2014","journal-title":"AAPS J"},{"key":"10.1016\/j.ejps.2019.105170_bib0050","article-title":"Establishment of virtual bioequivalence using population-based pbpk modelling: application to the setting of dissolution limits","author":"Pathak","year":"1997","journal-title":"AAPS J"},{"key":"10.1016\/j.ejps.2019.105170_bib0051","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.xphs.2018.11.034","article-title":"Biopharmaceutic IVIVE\u2014Mechanistic modeling of Single- and Two-Phase in vitro experiments to obtain drug-specific parameters for incorporation into PBPK models","volume":"108","author":"Pathak","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105170_bib0052","doi-asserted-by":"crossref","unstructured":"Pepin, X.J.H., Flanagan, T.R., Holt, D.J., Eidelman, A., Treacy, D., Rowlings, C.E., 2016. Justification of drug product dissolution rate and drug substance particle size specifications based on absorption pbpk modeling for lesinurad immediate release tablets.","DOI":"10.1021\/acs.molpharmaceut.6b00497"},{"key":"10.1016\/j.ejps.2019.105170_bib0053","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.ejmech.2004.06.012","article-title":"A topological sub-structural approach for predicting human intestinal absorption of drugs","volume":"39","author":"P\u00e9rez","year":"2004","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2019.105170_bib0054","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2125.1990.tb03691.x","article-title":"Inter- and intrasubject variability of gastric emptying in healthy volunteers measured by scintigraphy and paracetamol absorption","volume":"29","author":"Petring","year":"1990","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105170_bib0055","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1002\/jps.21759","article-title":"Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods","volume":"98","author":"Poulin","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105170_bib0056","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1007\/s11095-011-0506-6","article-title":"Precipitation in and supersaturation of contents of the upper small intestine after administration of two weak bases to fasted adults","volume":"28","author":"Psachoulias","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2019.105170_bib0057","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/07420529309059703","article-title":"Pharmacokinetics of single-dose administration of naproxen at 1O\u00a0: oo and 22\u00a0: oo hours","volume":"10","author":"Rao","year":"1993","journal-title":"Int. Soc. Chronobiol."},{"key":"10.1016\/j.ejps.2019.105170_bib0058","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.xphs.2018.10.044","article-title":"Application of a refined developability classification system","volume":"108","author":"Rosenberger","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105170_bib0059","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/jps.2600610507","article-title":"Absorption, distribution, metabolism, and excretion of naproxen in various laboratory animals and human subjects","volume":"61","author":"Runkel","year":"1972","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105170_bib0060","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3109\/03009747309097093","article-title":"Naproxen-metabolism, excretion and comparative pharmaco kinetics","volume":"2","author":"Runkel","year":"1973","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.ejps.2019.105170_bib0061","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1248\/cpb.20.1457","article-title":"Naproxen oral absorption characteristics","volume":"20","author":"Runkel","year":"1972","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.1016\/j.ejps.2019.105170_bib0062","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2174\/138920010794328913","article-title":"Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the \u201cAdvanced dissolution, absorption, metabolism (ADAM)\u201d model","volume":"11","author":"Darwich","year":"2010","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejps.2019.105170_bib0063","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1002\/jps.24162","article-title":"The biopharmaceutics risk assessment roadmap for optimizing clinical drug product performance","volume":"103","author":"Selen","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105170_bib0064","first-page":"142","article-title":"Effect of diffusion layer pH and solubility on the dissolution rate of pharmaceutical bases and their hydrochloride salts","volume":"74","author":"Serajuddin","year":"1985","journal-title":"I: Phenazopyridine. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105170_bib0065","first-page":"28","article-title":"Bioequivalence study with two naproxen sodium tablet formulations in healthy subjects","volume":"1","author":"Setiawati","year":"2009","journal-title":"J. Bioequivalence Bioavailab. -Open Access Res. Artic. JBB J Bioequiv Availab"},{"key":"10.1016\/j.ejps.2019.105170_bib0066","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/cpt.1013","article-title":"Physiologically based pharmacokinetic model qualification and reporting procedures for regulatory submissions: a consortium perspective","volume":"104","author":"Shebley","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2019.105170_bib0067","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1021\/mp800148u","article-title":"Toward an in vivo dissolution methodology: a comparison of phosphate and bicarbonate buffers","volume":"6","author":"Sheng","year":"2009","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2019.105170_bib0068","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1208\/s12248-017-0060-1","article-title":"Characterising drug release from immediate-release formulations of a poorly soluble compound, basmisanil, through absorption modelling and dissolution testing","volume":"19","author":"Stillhart","year":"2017","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2019.105170_bib0069","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1208\/s12248-018-0252-3","article-title":"Applications of clinically relevant dissolution testing: workshop summary report","volume":"20","author":"Suarez-Sharp","year":"2018","journal-title":"AAPS J"},{"key":"10.1016\/j.ejps.2019.105170_bib0070","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1208\/s12248-008-9023-x","article-title":"Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds","volume":"10","author":"Tubic-Grozdanis","year":"2008","journal-title":"AAPS J"},{"key":"10.1016\/j.ejps.2019.105170_bib0073","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-2125.1984.tb02454.x","article-title":"Naproxen pharmacokinetics in the elderly","volume":"18","author":"Upton","year":"1984","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105170_bib0074","first-page":"143","article-title":"Pharmacokinetics of high-dosage naproxen in elderly patients","volume":"26","author":"Van den Ouweland","year":"1988","journal-title":"Int. J. Clin. Pharmacol. Ther. Toxicol."},{"key":"10.1016\/j.ejps.2019.105170_bib0075","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/bdd.2510140605","article-title":"Pharmacokinetics of naproxen, its metabolite O\u2010desmethylnaproxen, and their acyl glucuronides in humans","volume":"14","author":"Vree","year":"1993","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2019.105170_bib0076","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/jps.10039","article-title":"General solution for diffusion\u2010controlled dissolution of spherical particles. 2. evaluation of experimental data","volume":"91","author":"Wang","year":"2002","journal-title":"J. Pharm. Sci"},{"key":"10.1016\/j.ejps.2019.105170_bib0077","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1021\/js980236p","article-title":"General solution for diffusion\u2010controlled dissolution of spherical particles. 1. theory","volume":"88","author":"Wang","year":"1999","journal-title":"J. Pharm. Sci"},{"key":"10.1016\/j.ejps.2019.105170_bib0072","unstructured":"U.S-FDA Center for Drug Evaluation and Research (CDER), 2018b. Physiologically based pharmacokinetic analyses \u2014 format and content guidance for industry."},{"key":"10.1016\/j.ejps.2019.105170_bib0071","unstructured":"U.S-FDA Center for Drug Evaluation and Research (CDER), 2018a. Physiologically based pharmacokinetic analyses \u2014 format and content guidance for industry."},{"key":"10.1016\/j.ejps.2019.105170_bib0078","unstructured":"Wedagedera, J., Cain, T., Pathak, S.M., Jamei, M., 2017. Virtual bioequivalence assessment of two tramadol formulations using the advanced dissolution absorption and metabolism (ADAM) model via simcyp R package."},{"key":"10.1016\/j.ejps.2019.105170_bib0079","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1023\/B:PHAM.0000016242.48642.71","article-title":"The \u201cHigh solubility\u201d definition of the current fda guidance on biopharmaceutical classification system may be too strict for acidic drugs","volume":"21","author":"Yazdanian","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2019.105170_bib0080","first-page":"523","article-title":"Integrating in vitro , modeling, and in vivo approaches to investigate warfarin bioequivalence. cpt pharmacometrics syst","volume":"6","author":"Zhang","year":"2017","journal-title":"Pharmacol"},{"key":"10.1016\/j.ejps.2019.105170_bib0081","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/clpt.2012.68","article-title":"Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions","volume":"92","author":"Zhao","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2019.105170_bib0082","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/jps.1031","article-title":"Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with Abraham descriptors","volume":"90","author":"Zhao","year":"2001","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105170_bib0083","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/j.1552-4604.1998.tb04469.x","article-title":"Single- and multiple-dose pharmacokinetic comparison of a sustained-release tablet and conventional tablets of naproxen in healthy volunteers","volume":"38","author":"Zhou","year":"1998","journal-title":"J. Clin. Pharmacol."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098719304439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098719304439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:50:46Z","timestamp":1760529046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098719304439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":83,"alternative-id":["S0928098719304439"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2019.105170","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2019.105170","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105170"}}